In addition, the expression of PPARα was increased in HFD-induced hepatic steatosis mice treated with the miR-34a inhibitor compared to the HFD-induced hepatic steatosis mice treated with the NC duplex (Fig. 3D and Figure S1E). Here, PPARA is linked to fatty liver disease.